A recent systematic review and meta-analysis showed that PD-L1 can effectively predict survival benefit in the patients with metastatic urothelial carcinoma (12), and soluble forms of PD-L1 and PD-1 in plasma samples can also predict sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma (13). This evidence concerns the gene CD274 and clear cell renal carcinoma.